Shield TherapeuticsSTU:1JS Net Current Asset Value is €-0.03 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 613 Drug Manufacturers companies, Shield Therapeutics ranks worse than 163131.97% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Shield Therapeutics's net current asset value per share for the quarter that ended in Dec. 2025 was €-0.03.
The historical rank and industry rank for Shield Therapeutics's Net Current Asset Value or its related term are showing as below:
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Shield Therapeutics was 86.94. The lowest was 3.70. And the median was 11.02.
STU:1JS's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.53 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Shield Therapeutics (STU:1JS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Shield Therapeutics Net Current Asset Value Related Terms
Shield Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1JS vs ZTS, UTHR, VTRS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €-0.03 mean?
Shield Therapeutics (STU:1JS) has a Net Current Asset Value of €-0.03 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shield Therapeutics and its competitors. Over the past decade, Shield Therapeutics' Net Current Asset Value has ranged from 3.70 to 86.94. According to the industry distribution chart, Shield Therapeutics ranks #999999 out of 613 companies in the Drug Manufacturers industry.
Is Shield Therapeutics' Net Current Asset Value too high?
Shield Therapeutics' current Net Current Asset Value is €-0.03. Over the past 10 years, this metric has ranged from a low of 3.70 to a high of 86.94. Based on the distribution chart, Shield Therapeutics ranks #999999 out of 613 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #999999 out of 613 companies for Net Current Asset Value. This places Shield Therapeutics in the lower half of its industry. The industry median Net Current Asset Value is 5.53. Historically, Shield Therapeutics' own Net Current Asset Value has ranged from 3.70 to 86.94 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.53, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Net Current Asset Value is €-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Net Current Asset Value is €-0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Net Current Asset Value is €-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 